Results 21 to 30 of about 923 (130)

Real-world data of Azvudine-induced hepatotoxicity among hospitalized COVID-19 patients in China: a retrospective case-control study [PDF]

Frontiers in Pharmacology
BackgroundThe COVID-19 pandemic, caused by the SARS-CoV-2 virus, has led to global health crisis. Although several antiviral drugs have been used to mitigate the severity and mortality of COVID-19, the safety profile remained a critical concern. Azvudine,
Yuanguo Xiong, Hao Xin, Cai Shi, Xianxi Guo, Ying Chen, Caifei Huang, Fuwang Ma, Ge Yang, Jian Yang   +8 more
doaj   +3 more sources

Association of Azvudine with severe outcomes among hospitalized patients with COVID-19 during an omicron-dominance period in Wuhan, China: a single-center, retrospective, matched cohort study. [PDF]

BMC Infect Dis
Constantly emerging SARS-CoV-2 genetic variants with potent immune escape kept the COVID-19 pandemic ongoing. Apart from vaccination, effective antiviral drug is necessary to achieve clinical improvement, especially for hospitalized patients.
Guo Z, Li W, Wang K, Lu Y, Gao S, Wang X, Zhao Y, Zhai Z, Chen B, Sun F, Zhao S, Cheng H.   +11 more
europepmc   +4 more sources

Real‐world effectiveness and safety of oral azvudine versus nirmatrelvir‒ritonavir (Paxlovid) in hospitalized patients with COVID-19: a multicenter, retrospective, cohort study [PDF]

Signal Transduction and Targeted Therapy
Azvudine and nirmatrelvir-ritonavir (Paxlovid) were widely used to treat patients with COVID-19 in China during the Omicron wave. However, the efficacy and safety of azvudine versus Paxlovid are poorly established. This study included 40,876 hospitalized
Haiyu Wang, Guangying Cui, Ming Cheng, Tuerganaili Aji, Guotao Li, Xinjun Hu, Guangming Li, Shixi Zhang, Yanyang Zhang, Linqi Diao, Pan Li, Ling Wang, Yiqiang Yuan, Guowu Qian, Ruiqing Zhang, Xiaoli Jin, Juan Wang, Hong Luo, Donghua Zhang, Mingming Wang, Silin Li, Zhan Song, Mengzhao Yang, Guanyue Su, Ranran Sun, Junbiao Chang, Zujiang Yu, Zhigang Ren   +27 more
doaj   +3 more sources

Azvudine reduces the in-hospital mortality of COVID-19 patients: A retrospective cohort study

Acta Pharmaceutica Sinica B, 2023
In our retrospective cohort study, we aim to explore whether Azvudine modifies the risk of death in COVID-19 patients. It was conducted on the medical records of patients, consecutively admitted for COVID-19 pneumonia to two hospitals in Chongqing, China.
Kaican Zong, Hui Zhou, Wen Li, E Jiang, Yi Liu, Shiying Li   +5 more
doaj   +4 more sources

Efficacy and safety of azvudine in patients with COVID-19: A systematic review and meta-analysis [PDF]

Heliyon, 2023
Introduction: Azivudine has undergone a few randomized controlled trials (RCTs) as of late. This study aimed to assess the COVID-19 treatment with azvudine's efficacy and safety.
Zhaoyan Chen, Fangyuan Tian
doaj   +4 more sources

Real-world effectiveness and safety of oral Azvudine versus Paxlovid for COVID-19 in patients with kidney disease: a multicenter, retrospective, cohort study [PDF]

BMC Infectious Diseases
Background Patients with kidney disease (KD) are at high risk of contracting COVID-19 and developing severe disease. There is still a lack of guidance regarding the treatment of COVID-19 in patients with KD.
Benchen Rao, Daming Wang, Mengzhao Yang, Chunyu Zhao, Ming Cheng, Silin Li, Donghua Zhang, Hong Luo, Guowu Qian, Ling Wang, Shixi Zhang, Guotao Li, Guangming Li, Zujiang Yu, Zhigang Ren   +14 more
doaj   +3 more sources

The effectiveness and safety of azvudine treatment in COVID‐19 patients with kidney disease based on a multicenter retrospective cohort study

View
Kidney disease has been the main risk factor of poor prognosis for COVID‐19 patients. The effectiveness and safety of azvudine treatment in COVID‐19 patients with kidney disease have not been reported. Herein, we conducted a nine‐center and retrospective
Bo Yu, Mengzhao Yang, Jia Yu, Daming Wang, Hong Luo, Ming Cheng, Shixi Zhang, Guotao Li, Ling Wang, Guowu Qian, Donghua Zhang, Silin Li, Zhigang Ren, Quancheng Kan   +13 more
doaj   +3 more sources

Effectiveness and safety of azvudine in older adults with mild and moderate COVID-19: a retrospective observational study [PDF]

BMC Infectious Diseases
Background Azvudine has clinical benefits and acceptable safety against COVID-19, including in patients with comorbidities, but there is a lack of available data for its use in older adult patients.
Zhiguo Zhou, He Zheng, Gui’e Xiao, Xiangping Xie, Jiaxi Rang, Danhong Peng   +5 more
doaj   +3 more sources

Effectiveness of azvudine versus nirmatrelvir/ritonavir for hospitalized patients with SARS-CoV-2 infection and pre-existing liver diseases [PDF]

Virology Journal
Background Azvudine and nirmatrelvir/ritonavir are recommended as priority treatments for SARS-CoV-2 infection in China, but their effectiveness and safety in patients with pre-existing chronic liver diseases remains unknown.
Guanyue Su, Feng Gao, Mengzhao Yang, Ling Wang, Lili Liang, Silin Li, Guangming Li, Na Han, Guotao Li, Guowu Qian, Shixi Zhang, Hong Luo, Donghua Zhang, Hongxia Liang, Zhigang Ren   +14 more
doaj   +3 more sources

Composite outcome of oral azvudine vs. nirmatrelvir-ritonavir in COVID-19 patients: a retrospective cohort study. [PDF]

Front Pharmacol
Objective To explore the effectiveness and safety of azvudine and nirmatrelvir-ritonavir in a real-world setting. Methods This retrospective cohort study included adult patients with confirmed COVID-19 who received azvudine or nirmatrelvir-ritonavir ...
Chen J, Liu Z, Liu R, Su C, Yang Y, Wang Z.   +5 more
europepmc   +4 more sources